I-INR idla ngokusetyenziswa ukulinganisa isiphumo se-anticoagulants yomlomo kwisifo se-thromboembolic. I-INR ende ibonwa kwi-anticoagulants yomlomo, i-DIC, ukungabikho kwe-vitamin K, i-hyperfibrinolysis njl. I-INR efinyeziweyo idla ngokubonwa kwiimeko ze-hypercoagulable kunye neengxaki ze-thrombotic. I-INR, eyaziwa ngokuba yi-International Normalized Ratio, yenye yezinto zokuvavanya umsebenzi we-coagulation. I-INR isekelwe kwi-reagent ye-PT yokulinganisa i-International Sensitivity Index kwaye ibale iziphumo ngeefomyula ezinxulumene nayo. Ukuba i-INR iphezulu kakhulu, kukho umngcipheko wokopha okungalawulekiyo. I-INR inokujonga ngokufanelekileyo kwaye isebenzise isiphumo se-anticoagulant drug. Ngokubanzi, kusetyenziswa i-warfarin ye-anticoagulant drug, kwaye i-INR kufuneka ihlolwe ngalo lonke ixesha. Kuya kufuneka wazi ukuba ukuba i-warfarin isetyenziswa, i-INR kufuneka ihlolwe rhoqo. Izigulana ezine-venous thrombosis kufuneka zithathe i-warfarin ngomlomo, kwaye ixabiso le-INR kufuneka ligcinwe ngokubanzi kwi-2.0-2.5. Kwizigulane ezine-atrial fibrillation, ixabiso le-inr le-warfarin yomlomo lihlala liphakathi kwe-2.0-3.0. Amaxabiso e-INR angaphezu kwe-4.0 anokubangela ukopha okungalawulekiyo, ngelixa amaxabiso e-INR angaphantsi kwe-2.0 engaboneleli ngempumelelo ngokuthintela ukujiya kwegazi.
Icebiso: usaya esibhedlele esiqhelekileyo ukuze uhlolwe, kwaye ulandele ilungiselelo likagqirha oqeqeshiweyo.
I-Beijing Succeeder igxile kwiimveliso zokuxilonga i-thrombosis kunye ne-hemostasis kwimarike yehlabathi.
Njengenye yezona mpawu ziphambili kwimarike yokuxilonga iThrombosis kunye neHemostasis eTshayina. I-SUCCEEDER inamava kumaqela e-R&D, iMveliso, iNtengiso yokuThengisa kunye neNkonzo, i-coagulation analyzers kunye nee-reagents, i-blood rheology analyzers ye-ESR kunye ne-HCT analyzers, i-platelet aggregation analyzers ene-ISO13485 CE Certification kunye ne-FDA ezidwelisiweyo.
Ikhadi leshishini
I-WeChat yesiTshayina